- Home
- CNTX vs PEPG Comparison
CNTX vs PEPG Comparison
Compare CNTX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- PEPG
- Stock Information
- Founded
- CNTX 2015
- PEPG 2018
- Country
- CNTX United States
- PEPG United States
- Employees
- CNTX N/A
- PEPG N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- PEPG Health Care
- Exchange
- CNTX Nasdaq
- PEPG Nasdaq
- Market Cap
- CNTX 67.7M
- PEPG 64.2M
- IPO Year
- CNTX 2021
- PEPG 2022
- Fundamental
- Price
- CNTX $0.81
- PEPG $1.37
- Analyst Decision
- CNTX Strong Buy
- PEPG Buy
- Analyst Count
- CNTX 5
- PEPG 3
- Target Price
- CNTX $6.70
- PEPG $14.67
- AVG Volume (30 Days)
- CNTX 147.9K
- PEPG 482.2K
- Earning Date
- CNTX 03-20-2025
- PEPG 03-05-2025
- Dividend Yield
- CNTX N/A
- PEPG N/A
- EPS Growth
- CNTX N/A
- PEPG N/A
- EPS
- CNTX N/A
- PEPG N/A
- Revenue
- CNTX N/A
- PEPG N/A
- Revenue This Year
- CNTX N/A
- PEPG N/A
- Revenue Next Year
- CNTX N/A
- PEPG N/A
- P/E Ratio
- CNTX N/A
- PEPG N/A
- Revenue Growth
- CNTX N/A
- PEPG N/A
- 52 Week Low
- CNTX $0.77
- PEPG $1.16
- 52 Week High
- CNTX $2.75
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- CNTX 39.82
- PEPG 31.82
- Support Level
- CNTX $0.77
- PEPG $1.16
- Resistance Level
- CNTX $0.87
- PEPG $1.60
- Average True Range (ATR)
- CNTX 0.08
- PEPG 0.14
- MACD
- CNTX 0.01
- PEPG 0.11
- Stochastic Oscillator
- CNTX 20.75
- PEPG 48.28
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.